ANKET

The companies will present pre-clinical data on Innate’s lead ANKET TM asset, IPH6101/ SAR443579, the first NKp46/CD16-based NK cell engager targeting CD123 These data highlight molecule’s favorable...

First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with mycosis fungoides that express KIR3DL2 New pre...

AstraZeneca to present new data on monalizumab in combination with durvalumab in a late-breaking abstract on COAST Phase 2 trial Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the...

Proprietary, multi-specific NK cell engager platform, ANKET™, to generate next wave of immunotherapy molecules ANKET is first NK cell engager technology to engage NKp46, CD16, IL 2 variant and tumor...

• Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphoma • Company’s...

IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format Selection of IPH6101/SAR443579 triggers a €7M milestone payment to Innate Innate...

Cash, cash equivalents and financial assets of the Company amounted to €215.2 million* $79.1 million (€71.4 million**) in gross proceeds from our IPO on the Nasdaq and Global Offering Monalizumab to...

Preclinical data showcases advancement of its immuno-oncology portfolio across the Company’s three strategic pillars: immune checkpoint inhibitors, tumor antigen targeting and tumor micro-environment...

The findings describe potential first-in-class NKp46 NKCEs, a new generation of multifunctional antibody-based molecules for fighting cancer The NKCE technology provides a versatile platform to...

New preclinical data highlights IPH5201 (anti-CD39) and IHP5301 (anti-CD73) neutralizing antibodies targeting the immunosuppressive adenosine pathway First data presented from Innate Pharma’s...